Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

CHEK2 (∗) 1100delC Mutation and Risk of Prostate Cancer

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. First danish single-institution experience with radical prostatectomy: biochemical outcome in 1200 consecutive patients.

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Although the causes of prostate cancer are largely unknown, previous studies support the role of genetic factors in the development of prostate cancer. CHEK2 plays a critical role in DNA replication by responding to double-stranded breaks. In this review, we provide an overview of the current knowledge of the role of a genetic variant, 1100delC, of CHEK2 on prostate cancer risk and discuss the implication for potential translation of this knowledge into clinical practice. Currently, twelve articles that discussed CHEK2 (∗)1100delC and its association with prostate cancer were identified. Of the twelve prostate cancer studies, five studies had independent data to draw conclusive evidence from. The pooled results of OR and 95% CI were 1.98 (1.23-3.18) for unselected cases and 3.39 (1.78-6.47) for familial cases, indicating that CHEK2 (∗)1100delC mutation is associated with increased risk of prostate cancer. Screening for CHEK2(∗)1100delC should be considered in men with a familial history of prostate cancer.

Original languageEnglish
JournalProstate Cancer
Volume2014
Pages (from-to)294575
ISSN2090-3111
DOIs
Publication statusPublished - 2014

ID: 44848071